Terbium-149 (Tb-149) is emerging as a distinctive radionuclide in the targeted alpha therapy landscape, offering a rare combination of high-linear-energy-transfer α-particle emission and partial positron decay that enables both potent tumor cell eradication and real-time biodistribution tracking. At Protheragen, we translate these unique physical properties into actionable radiopharmaceutical candidates through our integrated Tb-149 radiolabeling service, supporting clients from early-stage vector selection through to preclinical proof-of-concept.
Tb-149 is a radioisotope of the lanthanide terbium with a half-life of approximately 4.1 hours, decaying primarily via alpha emission (Eα = 3.97 MeV, 16.7% branching ratio) while also exhibiting electron capture (76%) and positron emission (7.1%). This dual decay profile is particularly significant in nuclear medicine: the alpha particles deliver a linear energy transfer (LET) of 140–142 keV/μm across a tissue range of only 25–28 μm, enabling highly localized DNA double-strand breaks in tumor cells with minimal collateral damage to surrounding healthy tissue. Unlike some alternative alpha emitters, Tb-149 does not generate alpha-emitting daughter nuclides in its decay chain, substantially reducing the risk of off-target radiotoxicity from recoiling daughter atoms. The co-emission of positrons further allows post-therapeutic PET imaging using the same radiolabeled vector, positioning Tb-149 as a true theranostic radionuclide capable of merging therapy and diagnostics within a single molecular construct.
Fig 1. Summary of the physical characteristics of the radioisotopes of terbium. (Sancho, L., et al., 2025)
From a radiochemistry perspective, Tb-149 behaves chemically as a trivalent lanthanide cation (Tb3+), exhibiting strong coordination affinity for macrocyclic bifunctional chelators such as DOTA, DOTA-GA, and NETA derivatives. This chemical homology with clinically established lutetium-177 means that well-validated labeling protocols, quality control assays, and conjugation strategies can be directly adapted or optimized for Tb-149 with minimal re-engineering of the targeting vector. Preclinical studies have demonstrated successful Tb-149 labeling of somatostatin analogues (DOTATATE, DOTANOC), folate receptor ligands, and antibody constructs, with subsequent in vivo PET/CT imaging confirming favorable tumor uptake and pharmacokinetic profiles in xenograft models. However, the relatively short half-life of 4.1 hours imposes stringent demands on radiolabeling efficiency, reaction kinetics, and rapid purification workflows, making specialized expertise and infrastructure essential for reproducible, high-specific-activity formulations.
Protheragen bridges the gap between Tb-149 radiochemistry innovation and practical preclinical application. Our dedicated radiochemical services team operates within a fully equipped radiopharmaceutical development facility, offering end-to-end support that encompasses vector-chelator conjugation, radiolabeling optimization, radiochemical purity verification, in vitro stability assessment, and in vivo biodistribution validation. Whether your program requires a standard DOTA-based peptide conjugate or a complex antibody-derived construct, we tailor each Tb-149 labeling campaign to your specific molecular target, desired specific activity, and downstream analytical requirements.
Synthesis and characterization of DOTA, DOTA-GA, NETA, or custom bifunctional chelator conjugates; determination of chelator-to-vector molar ratios; HPLC and LC-MS purity verification.
Systematic optimization of pH, temperature, reaction time, and ligand concentration to achieve maximum radiochemical conversion (RCC); typical conditions range from pH 4.0–5.5 and 40–95°C depending on vector thermal stability.
ITLC, HPLC, and solid-phase extraction (SPE) methods for >98% radiochemical purity confirmation; apparent molar activity quantification up to 50 MBq/nmol or higher depending on vector class.
Serum stability evaluation at 37°C over 24–72 hours; cell-binding affinity measurements (Kd determination) on target-expressing cell lines; competitive binding assays against reference standards.
Design and execution of mouse/rat biodistribution studies; PET/CT imaging coordination for Tb-149 positron-emission tracking; tissue dosimetry calculations and pharmacokinetic modeling.
Comprehensive batch records, radionuclidic purity certificates, and stability data packages formatted for IND-enabling preclinical study submissions.
Each Tb-149 labeling project at Protheragen follows a structured, milestone-driven workflow designed to accommodate the short half-life of the radionuclide while ensuring robust data generation and reproducibility. From initial consultation through final reporting, we emphasize transparent communication, real-time reaction monitoring, and adaptive protocol refinement.
1. Project Consultation & Feasibility Assessment — We review your target vector, proposed chelator system, and intended application (therapy, imaging, or theranostics) to define realistic labeling parameters, expected specific activity, and recommended quality control assays.
2. Vector Preparation & Conjugation — If required, we synthesize or procure the bifunctional chelator-vector conjugate, verify its chemical identity by LC-MS, and confirm the absence of aggregation or degradation prior to radiolabeling.
3. Radiolabeling Reaction Execution — Tb-149 chloride is introduced under optimized conditions (buffer, pH, temperature) with continuous monitoring; reaction progress is tracked by ITLC to determine RCC and guide real-time parameter adjustments.
4. Purification & Formulation — The labeled product is purified via SPE, HPLC, or size-exclusion chromatography to remove unbound metal and byproducts, then formulated in a suitable buffer (e.g., saline, acetate, or ascorbate) for stability.
5. Quality Control & Release Testing — Comprehensive QC includes radiochemical purity (>98% target), radionuclidic identity, pH, osmolality, endotoxin screening, and sterility assessment where applicable; all data are compiled in a signed release certificate.
6. Stability Evaluation & In Vitro Characterization — Accelerated and real-time stability studies in human serum and formulation buffer; cell-binding assays to confirm retention of biological activity post-labeling.
7. In Vivo Validation & Reporting — Biodistribution or imaging studies in relevant animal models; final report includes raw data, statistical analysis, and recommendations for scale-up or clinical translation.
If you are exploring Tb-149 as a next-generation alpha-therapeutic platform or seeking a reliable partner to advance your radiopharmaceutical pipeline, we invite you to reach out to our radiochemistry team today. Contact us to discuss your project requirements, receive a customized service proposal, or schedule a consultation with our nuclear medicine specialists. Let Protheragen help you transform the therapeutic potential of terbium-149 into clinically meaningful progress.
Reference